CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
The New England journal of medicine, 384(23): e91 PMID 34107196 DOI 10.1056/NEJMc2103481
Abstract
This article has no abstract in PubMed.
Your browser does not allow saving data (e.g. private mode): bookmarks will be lost when the tab closes.